EUROPE HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • EUROPE HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

EUROPE HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

 The Europe hyperphosphatemia drug market generated a revenue of $xx million in the year 2018. It is a fast-growing market with an expected CAGR of 15.63% for the forecast period of 2019-2027. The market is anticipated to generate $xx million by the end of this forecast period. The countries analyzed for this region include the United Kingdom, France, Germany, Spain, Italy and the Rest of Europe.

EUROPE HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

Europe Hyperphosphatemia Drugs Market by Formulation (Calcium-based Phosphate Binders, Aluminum-based Phosphate Binders, Magnesium-based Phosphate Binders, Iron-based Phosphate Binders) & by Geography

Request free sample

Report Summary

The Europe hyperphosphatemia drug market generated a revenue of $xx million in the year 2018. It is a fast-growing market with an expected CAGR of 15.63% for the forecast period of 2019-2027. The market is anticipated to generate $xx million by the end of this forecast period.

The countries analyzed for this region include the United Kingdom, France, Germany, Spain, Italy and the Rest of Europe. The occurrence of chronic diseases like diabetes and hypertension which in turn leads to hyperphosphatemia is on the rise in these regions, thus boosting the scope of the hyperphosphatemia drug market expansion. Also, a growing ageing population in these countries coupled with unattended medical needs is acting as a major driver for the market growth.

A majority of companies are focusing on product launches in the hyperphosphatemia drugs maarket. Some of them include Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, Bruno Pharmaceutical Spa, Fermenta Biotech Ltd, Pfizer Inc., Roche Diagnostics Corporation, DSM Biotech Pharmacal, Vifor Pharma, Shire, Fresenius Medical Care, Amag Pharmaceuticals, R.H. Moore Drug Co, Johnson and Johnson, Sanofi, Cipla, and Ultragenyx.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Table of Contents

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
    • ESTIMATION METHODOLOGY
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • IRON-BASED HYPERPHOSPHATEMIA DRUGS IS A GAME CHANGER
  1. MARKET DETERMINANTS
    • DRIVERS
      • GROWING PREVALENCE OF CHRONIC DISEASES
      • UNMET MEDICAL NEEDS
      • SKEWED POPULATION MIX TOWARDS ELDERLY PEOPLE
      • RISE IN PUBLIC AWARENESS
    • RESTRAINTS
      • LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION (FDA)
      • GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
    • CHALLENGES
      • NON-ADHERENCE TO TREATMENT REGIMENS
      • SIDE EFFECTS OF DRUGS
      • LIMITED AVAILABILITY OF DRUGS
      • USE OF ADVANCED DIALYSIS TECHNIQUES
  1. MARKET BY DOSAGE
    • SOLID
      • TABLET
      • POWDER
    • LIQUID
      • SOLUTION
  1. MARKET SEGMENTATION
    • MARKET BY FORMULATION 2019-2027
      • CALCIUM-BASED PHOSPHATE BINDERS
      • ALUMINUM-BASED PHOSPHATE BINDERS
      • MAGNESIUM-BASED PHOSPHATE BINDERS
      • IRON-BASED PHOSPHATE BINDERS
      • OTHER PHOSPHATE BINDERS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF SUBSTITUTE PRODUCT
      • INTENSITY OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • KEY BUYING CRITERIA
      • APPLICATION
      • PRICING
      • EFFECTIVENESS
      • AVAILABILITY
    • MARKET TRENDS
      • PATIENT ASSISTANCE PROGRAMS
      • STRATEGIC ALLIANCES
      • INCREASE IN R&D
  1. GEOGRAPHIC ANALYSIS
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE (ROE)
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
    • BRUNO FARMACEUTICI SPA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • FERMENTA BIOTECH LTD
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AMAG PHARMACEUTICALS
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • JOHNSON AND JOHNSON
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SANOFI
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SHIRE
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • FRESENIUS MEDICAL CARE
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • CIPLA
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ROCHE DIAGNOSTICS CORPORATION
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BIOTECH PHARMACAL
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SUN PHARMACEUTICAL INDUSTRIES LTD
      • OVERVIEW
      • PRODUCTS PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ZERIA PHARMACEUTICAL
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • KERYX BIOPHARMACEUTICALS INC
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ROYAL DSM N.V.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ULTRAGENYX PHARMACEUTICAL INC.
      • OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES

TABLE LIST

TABLE 1       EUROPE HYPERPHOSPHATEMIA DRUG MARKET 2019-2027($ MILLION)

TABLE 2       IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2018

TABLE 3       PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 4       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027($ MILLION)

TABLE 5       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 6       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 7       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 8       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 9       EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)

TABLE 10     PIPELINE PORTFOLIO OF HYPERPHOSPHATEMIA DRUGS

TABLE 11     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET, 2019-2027 ($ MILLION)

 

FIGURE LIST 

FIGURE 1     RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 2     DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

FIGURE 3     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 4     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 5     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 6     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 7     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)

FIGURE 8     PORTER’S 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET

FIGURE 9     EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE, 2018 & 2027 (%)

FIGURE 10   EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 11   UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 12   FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 13   GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 14   SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 15   ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 16   REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)

FIGURE 17   MARKET SHARE ANALYSIS OF KEY PLAYERS 2018 (%)

Segmentation

  1. GEOGRAPHIC ANALYSIS
    • EUROPE
      • UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • ITALY
      • REST OF EUROPE (ROE)
  1. MARKET SEGMENTATION
    • MARKET BY FORMULATION 2019-2027
      • CALCIUM-BASED PHOSPHATE BINDERS
      • ALUMINUM-BASED PHOSPHATE BINDERS
      • MAGNESIUM-BASED PHOSPHATE BINDERS
      • IRON-BASED PHOSPHATE BINDERS
      • OTHER PHOSPHATE BINDERS

Request Free Sample

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now

Inkwood Research